Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn’s disease: results from the phase 3 VIVID-1 study

TL;DR

This study shows that mirikizumab improves fatigue in Crohn’s disease patients more than placebo, with improvements linked to better quality of life and clinical outcomes.

Contribution

The study is the first to demonstrate mirikizumab's impact on fatigue in Crohn’s disease patients and its correlation with clinical outcomes.

Findings

Mirikizumab-treated patients showed higher rates of fatigue improvement compared to placebo at Weeks 12 and 52.

Improvements in fatigue were strongly associated with better quality of life and patient-reported outcomes.

Baseline fatigue severity was strongly linked to depressive symptoms in patients.

Abstract

Fatigue is a debilitating multifactorial symptom experienced by patients with Crohn’s disease (CD). Mirikizumab, an anti-interleukin-23p19 antibody, demonstrated significant efficacy and safety in the patients with moderately to severely active CD. This analysis investigated the impact of mirikizumab on fatigue and the association between changes in clinical, endoscopic, and patient-reported outcomes with improvement in fatigue from baseline in the Phase 3 VIVID-1 study.

Adult patients with moderately to severely active CD that failed at least 1 biologic agent or conventional therapy were randomized to receive mirikizumab or placebo. Fatigue was assessed via the validated Functional Assessment of Chronic Illness Therapy-Fatigue questionnaire. Fatigue associations with patient-reported outcomes, endoscopic, and clinical measures were assessed via Pearson correlation analysis.

At Week 12, 43% and 33%, and at Week 52, 46% and 36% of mirikizumab-treated patients achieved ≥ 6 and ≥ 9 fatigue score improvements vs placebo (Week 12, 31%, 22%; Week 52, 20%, 16%), respectively. Baseline fatigue scores were strongly associated with depressive symptoms and moderately associated with quality of life (QoL) at baseline. Improvements in fatigue at Weeks 12 and 52 were strongly associated with QoL and patient-reported outcomes and weakly with objective markers of inflammation and disease activity.

Mirikizumab-treated patients with CD achieved higher rates of clinically meaningful improvement in fatigue vs placebo at Weeks 12 and 52, which correlated with improvement in clinical and patient-reported outcomes. Baseline fatigue severity was strongly associated with depressive symptoms in VIVID-1 (NCT03926130).

Figures